Hon Kam Lun, Kung Jeng Sum, Ng Wing Gi Gigi, Leung Ting Fan
Department of Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong.
Curr Pediatr Rev. 2019;15(3):191-195. doi: 10.2174/1573396315666190415144244.
To describe the methodology in studying patient's acceptability and efficacy of an ectoin containing emollient for atopic dermatitis (AD).
We described the methodology that we used in studying emollients and moisturisers, and patient acceptability of a group of AD patients before and following usage of an ectoin-containing proprietary emollient. These data were also compared with other brand emollients that we previously reported, namely Restoradom®, Ezerra® and Ezerra plus®.
30 subjects (50% Male, Mean (SD) age: 9.8 (3.6) years with AD used the trial emollient W for four weeks. AD severity of subjects (by objective SCORAD) was moderate (n=22) and severe (n=8). Compliance was good and patients generally managed to use the moisturisers daily, with individual reports of a 'tingly' sensation by some subjects when applied to inflamed wounds. 63% reported "very good" or "good", whereas 37% reported "fair" or "poor" acceptability of the moisturisers. Following use of the trial emollient, area affected, disease intensity and severity significantly improved, as demonstrated in objective SCORAD (p=0.002). There were also significant improvements in POEM (p=0.035), and PADQLQ scores (p=0.017). For skin measurements, only transepidermal water loss had improved (p=0.035) after the treatment. There was no significant improvement of itch or sleep scores, skin hydration, pH, S. aureus colonization status, or need for use of topical medications. When compared with historical data of other emollients, the mean age of patients on emollient W was younger; efficacy and acceptability among these emollients were similar.
Methodology of emollient research is described. Doctors should provide evidencebased information about the efficacy of emollients. The ectoin-containing proprietary emollient improves disease and quality of life following its use in 4 weeks. Efficacy and acceptability are similar among 4 proprietary emollients.
描述研究含依克多因的润肤剂对特应性皮炎（AD）患者的可接受性和疗效的方法。
我们描述了在研究润肤剂和保湿剂以及一组AD患者在使用含依克多因的专利润肤剂之前和之后的患者可接受性时所采用的方法。这些数据还与我们之前报告的其他品牌润肤剂，即Restoradom®、Ezerra®和Ezerra plus®进行了比较。
30名患有AD的受试者（50%为男性，平均（标准差）年龄：9.8（3.6）岁）使用试验润肤剂W四周。受试者的AD严重程度（通过客观SCORAD评分）为中度（n = 22）和重度（n = 8）。依从性良好，患者通常能够每天使用保湿剂，一些受试者报告在涂抹于发炎伤口时有“刺痛”感。63%的受试者报告润肤剂的可接受性为“非常好”或“好”，而37%的受试者报告为“一般”或“差”。使用试验润肤剂后，如客观SCORAD评分所示，受影响面积、疾病强度和严重程度显著改善（p = 0.002）。POEM（p = 0.035）和PADQLQ评分（p = 0.017）也有显著改善。对于皮肤测量，治疗后仅经表皮水分流失有所改善（p = 0.035）。瘙痒或睡眠评分、皮肤水合作用、pH值、金黄色葡萄球菌定植状态或外用药物使用需求均无显著改善。与其他润肤剂的历史数据相比，使用润肤剂W的患者平均年龄更年轻；这些润肤剂的疗效和可接受性相似。
描述了润肤剂研究的方法。医生应提供关于润肤剂疗效的循证信息。含依克多因的专利润肤剂在使用4周后可改善疾病状况和生活质量。4种专利润肤剂的疗效和可接受性相似。
